‘TRIMURTHI DRUGS & PHARMACEUTICALS umes MURT Fil STAN TALONE AUDITED QUARTERLY RESULTS FOR THE YEAR ENDED JUNE, 2035 FRR Ta oF SANDSTONE UNAUDITED RESULTS FOR QUGRTERTAND REE HONTHS ENDED 7-955 Partaulrs SEA OARS eding 3 ouresponding 3] Year ended Months [Provence | months ended | 33-03-2035 soc00-2015 ended 31-03+ "30-06-2014 ois ranater oom | rane [nod income From Oneratons eS Ree Comat TH TE Ta aa vie Gperaing come Hoe{ 078 zest Tea ar Operating Taconite) Fie | 306 | a7 7s a [espendiare fa, Consumption of Raw Material Nr wr ii PE peehaae aed Cond ST —_ 7 TE (e-{increase)/ Decrease In stock in trade and work in gree 000 000 nai na. ar Co ta Sr Hay aa fs baecaton ees a a7 [f. Other Expenditure 6.16 2.66 6.37, 37.74 tal Teis| 4208 a0 nas Op eTtORS DETOTS OT rer pian Cost & exceptional Items (2 2. [yy 232| 130) oat 2980 ohne "is 3) 60 i) rote (Lost trom Ordinary Activites efor 5. [Pontos Cos Ereaptonal Teems (334) sss| corsa) 1031 937 Sena cor 00 ae i i a Sey rom OPA SCT aT Vara cont but before exceptional tems (S29) sas| _(s207] oat 278 eee a ci i i See tase rom Ordinary aaa DTare tax 728) css| _cs207 oa 8 a ee ing DoT iar ca) 30 ae Fo tay (ess) om Ordinary Sever iter Tx (9310) sa| sss) eo 186 a er anor Ta Eee cm *t mt 3, [Net Profit/ (Loss) for the period (11412) (25.98) 6.61 1.86 ner eee =f ar a re ey Test et 3 hk Scere tare, TOT rare and share Of Prof (oss) of 16, aneoctes (13246225) sa1| 598) eo. 1.86 ies ae Ear oar TE TET 17 exe) oo0| _e1o0 1000 000 STG ORNS TT a [pone sheet of pevusacountng yor san| sae 29326 saa 15-{earings Per Share (EPS) ES aorta ROT ced oos| cosa 008 0.02 ta ar eTaaTaTITy Kee (not annualised) oos| 32) 08 02 po Trimorthi Drugs §-Poprmaceatifals Lid, Trimurthi Drugs & Pharmaceuticals Lid. a ee [231/12 A8C, ner Bagh Suton Bare Hyderabad - 500 095, A.P.. Inia pea ¥:040 2475 7370 W: wwwrtrimurthigroup.com CIN No: L67120TG1994PLC018956TRIMURTHI ‘TRIMURTHI DRUGS & PHARMACEUTICALS LIMITED GROUP ‘STANDALONE AUDITED QUARTERLY RESULTS FOR THE QUARTER ENDEC Un) 2035 " ‘SELECT INFORMATION FOR QUARTER I AND THREE MONTHS ENDED 30-06-2015 Santis” Praceaing [Corresponding 3] — Year ened ‘months | months ended | 31-03-2015, ‘96-2015 |endea 31-03-| "30-06-2014 ‘ois aU aa ie =e lene coms ‘Segment Reporting artcuare [Ne Sales] tncome From Operations ‘sos: ‘The ave ess have been taken on record he ow of recs he company a tha meng held on 13-062015, 2 The an ress ort quarter ended 3.62015 hve ben reves bythe stator urs purse ot ising agent 9. Insegrare repr commen ass tat ae used tercangeble rot lees tothe nda segment above, for Trimurthi Drags & Faarmacentibale Ltd, Trimurthi Drugs & Pharmaceuticals Ltd. 4-4-231/1/2 ABC. indir Bagh, Sultan Bazar, ~ pirecroe Hyderabad! 500 095: AP- Indio 12040 2475 7370 CIN No: £67129 TG1994PLC 1395 956 Www Arimutthigroup.comTRIMURTHI DRUGS & PHARMACEUTICALS LIMITED TRIMURTHI CONSOLIDATED UNAUDITED QUARTERLY RESULTS FOR THE QUARTER ENDED JUNE, 2015 GROUP — PARTI (Rea Laks) PART EENT OF CONSOLIDATED UNAUDITED RESULTS FOR QUARTER I AND THREE MONTHS ENDED 30/06/2035 [Particulars Months |Preceeding 3 | Corresponding | Year ended ‘ended | months | 3months | 31-03-2015 30-06-2015| _ ended ‘ended 31-03-2015 | 30-06-2014 Unaudited | Unaudited | Unaudited | Audited [1,_Income From Operations, Net Sales / Income from Operations Ts T0034 TST SHS [other Operating Income 23.76) 39.98 26.87 123.45 Operating Inconve(Net) 728.90 740.32 174.58 634.96 [2._[expenditure. fa Consumption of Raw Material Ni Ti a 7 fb. Purchase of Traded Goods 13.30 35.64 TET WEz4 fe-(Increase}/Decresse in stock In Wade and work Th Progress 0.86, 432 3.0 12.80) i. Employees Coat 11.46 7718) 4.76, 35.86, [e. Depreciation 3.81 1737 7.66, 40.89 [Other Expenciture 9.65, 25.78 33 50.63 [Total 740.08 761.28 156.27 386.82 iprofit/ (Loss) from Operations before Other 3, |tmeome, Finance Cost & Exceptional Ttems (2-1) 8.83 (20.98), 18.30 48.14 [ax Jother income: 456) 20:63) 0.007 120.63) lprofit/ (Loss) from Ordinary Acitivites before 5. |Finance Cost & Exceptional Items (34) 13.39 (41.59) 18.30 27.51 i6._|Finance Cost 0.00 O13, 0.00) 0.39 7. lprofit/ (Loss) from Ordinary activities after finance cost but before exceptional items (546) a339| (41.72) 18.30 27.42 [&_[Excepbonal Items NI Ni Ni Ni [5,- Profit] (Loss) from Ordinary activities before tax 738) 13.39 (41.72) 18.30 27.42 Hi [tax expense (Including Deferred Tax) 361 E73) 6.02 12.94 iI, |Net Profit/ (Loss) from Ordinary activities after Itax (9:+10) 9.78 (33.00), 12.28 34.8 Hr [extraorindary Tems{Net OF Tax Expenses) Ni Ni Nt NI 13, |Net Profit) (Loss) for the period (11.412) 9.78 (33.00), 12.28 14.18 4 [Share OF Prof (oss) Of Associstes NA" NAS =NAS =WA 15. |Pinonty Interest 178 (2.26)| NAY 5.67 [Net Profit] (Loss) after taxes, Minority Taterest land Share Of Profit/(Loss) of Associates 16, (03414415) 8.00 (30.74)| 12.28 8.51 17, [paid-up Equity Share Capital (Face Value of Rs.10/- each) 810.00 810.00 310.00 810.00 Reserits exclading revaluation reserves as per balance 18, sheet of previous accounting year 332.90 336.82 344.80 336.82 79. [Earnings Per Share (EPS) [Basic & Diluted before extraordinary Ttems (not annualised) 0.10 (0.38)| 0.15 0.11 asic & Diluted after extraordinary Weems (not p 0.10 (0.38) 0.15 ott Trimurthi Drugs & Pharmaceuticals Ltd. 44-231/1/2 ABC, Inder Bagh, Sultan Bazar, Hyderabad - 500 095, AP. India T:040 2475 7370 W: wen. rimurthigroup.cor mC LN Noi £67120 Bor Trimorthi Di TG 1g9aPECoss956 Phacmacghticaly Lt DIRECTSSelect Informéion for Quarter I and Three months Ended 30/06/2085 ‘3 Months /Preceeding 3] Correspondi Year fsnded | months | 3months "| 31-03-20 30-06-2015 ended 31-03-| * ended 2015 | 30-06-2015, ote grou nc Deo “=o moter and rameter go rae plaints stor ae Te re guarer ig the quar nang used di Segment Reporting Particulars [Segment Revenue fa Pama Suse areal e Invesents ig Tacing Sia ess: Ter Sagment Revenue lt Sales/ Income Fron ment Profits (before tax fa. Ptma Bos 3 [bP services le Testes Teng ee li Other UTS i Ueaocabie income 7 =H Taz El i531 & a. Pharma Buss i Tnvestens = iD 7 zz To7Oa 5 a a0 112290 3187.65 114598| 132290 te i + Ramat oem apt Lonny tot tytn 2 ote econ ha neem neti anrnel sf a sgn tt reine peace ft ms rman troy Pe i ramurths Drugs rimurthi Driggs & Pharmaceuticals ltd. *# ar 4-224 /1/2 ABC. lider Bagh, Sulton Bazar, Hyderabad - 5001995, AP. India (040 2475 7370 i : C018956 Voarretneornilfoup.con€lN No: L67120TG1994PLCOr IMURTHI GROUP— armaceutyfals Lre aes DIRECTOR= Phone: 40079475 Mobile: 83910 04760, K. Venkateswara Rao & Associates Chartered Accountants Door No. 3-6-807/2, Fiat No.402. Mahavir Lok. Himayathnagar Mein Road, Hyderabad - 500 029. ‘e-mal:v_kommineni@yahoo.com Annexure V to Clause 41 Review Report to: ‘The Board of Directors, Trimurthi Drugs & Pharmaceuticals Limited We have reviewed the accompanying statement of unaudited financial results of M/s TRIMURTHI DRUGS & PHARMACEUTICALS LIMITED for the period ended 30" June, 2015. This statement is the responsibility of the Company’s Management and has been approved by the Board of Directors/committee of Board of Directors. Our responsibility is to issue a report on these financial statements based on our review. We conducted our review in accordance with the Standard on Review Engagement(SRE) 2400, Engagements to Review Financial Statements issued by the Institute of Chartered Accountants of India, This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement, A review is limited primarily to inquires of company personnel and analytical procedures applied to financial data and this provides less assurance than an audit, We have not performed an audit and accordingly, we do not express an audit opinion. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards (Note 1) and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which itis to be disclosed, or that is contains any material misstatement. — K.VENKATESWARA RAO & SS@ORHS PLACE : HYDERABAD PROPRIETOR M.No. 27305